Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Phase 2 N=58 Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or…
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Phase 2 N=61 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Esophageal Cancer · Gastric Cancer
Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants
Phase 2 N=63 S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Overall Survival at 6 Months — 36 percentage of participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
Phase 2 N=44 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Determine Pathologic Complete Response — 9 Participants
Phase 2 N=41 Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
Esophageal Cancer
Primary: Complete Pathologic Response (pCR) — 36.6 percentage of participants
Phase 2 N=126 Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
Esophageal Cancer · Gastroesophageal Cancer
Primary: Pathologic Complete Response Rate — 13; 26 percentage of participants
Phase 2 N=110 Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
Esophageal Cancer
Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants
Phase 2 N=65 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants
Phase 2 N=202 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83
Phase 2 N=62 Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
Esophageal Cancer
Primary: Pathologic Complete Response (pCR) Rate — 18 Participants
Phase 2 N=4 Trimodality Management of T1b Esophageal Cancers
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Phase 2 N=25 Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Progression-free Survival Rate — 7 weeks
Phase 2 N=74 Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Phase 2 N=35 Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Esophageal Cancer · Gastroesophageal Junction Cancer
Primary: 2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer. — 20; 14; 1…
Phase 2 N=62 Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Pathologic Complete Response (PCR) — 28.6; 40.7 percentage of participants
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 2 N=245 Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma — 61; 45; 54 percentage of participants
Phase 2 N=35 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Undifferentiated Carcinoma · Gastric Adenocarcinoma
Primary: Overall Response Rate — 26 percentage of participants
Phase 2 N=34 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Evaluation of Safety and Toxicity — 1; 1; 1; 1 participants
Phase 2 N=12 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Comparison of Progression-free Survival — 6.1; 2.4 Months — p=0.43
N/A N=50 Esophageal Cytology With FISH in Detecting Esophageal Cancer
Dysphagia · Dysplasia · Esophageal Adenocarcinoma
Primary: Sensitivity of Sponge Cytology Using FISH — 13.3 percentage of cases among positive tests
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Phase 3 N=546 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Overall Survival — 3.6; 3.5 years
Phase 2 N=6 Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
Resectable Esophageal Cancer · GastroEsophageal Cancer
Primary: Number of Participants With Dose Limiting Toxicity — 0 Participants
Phase 2 N=97 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Pathologic Complete Response Rate — 15.4; 16.7 percentage of participants
Phase 2 N=6 Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Adenocarcinoma of the Esophagus · Adenocarcinomas of the Gastroesophageal Junction · Recurrent Esophageal Cancer
Primary: Overall Response — 2; 4 patients